DNAnexus, Inc., a Mountain View, CA-based biomedical informatics and data management company, closed a $58m financing.
The round was led by new investor Foresite Capital with strategic investment from Microsoft (NASDAQ: MSFT) and existing investors GV (formerly Google Ventures), TPG Biotech, WuXi NextCODE, Claremont Creek Ventures, and MidCap Financial.
The company intends to use the funds for the continued expansion in the clinical trials market as well as the deployment of its Translational Informatics Suite for pharmaceutical and other research organizations.
Led by Richard Daly, Chief Executive Officer, DNAnexus has developed a global platform that enables a network of enterprises to gain insight from large genomic and biomedical datasets. Earlier this year, the company launched the Mosaic™ Microbiome Platform to advance methods aimed at increasing the understanding of the human microbiome and an early access program for Google Brain’s DeepVariant technology. It also announced separate collaborations with AstraZeneca’s Centre for Genomics Research and Rady Children’s Institute for Genomic Medicine.